

## **NUMIRA BIOSCIENCES TO PRESENT POSTER AT WORLD MOLECULAR IMAGING CONGRESS**

*Numira to present novel method for analyzing pulmonary fibrosis in animal models using MicroCT Imaging and Three Dimensional Volumetric Analysis*

**SALT LAKE CITY, Utah, August 25, 2011** –Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, today announced that they have been invited to present their current research in the area of pulmonary fibrosis at the upcoming World Molecular Imaging Congress (WMIC) on September 8<sup>th</sup>. The conference is being held at the San Diego Conference Center, on September 7-10, 2011, in San Diego.

The abstract, “MicroCT Imaging and Three Dimensional Volumetric Analysis of Bleomycin Induced Pulmonary Fibrosis in Pre-clinical Mouse Specimens,” summarizes the latest development in microCT imaging in determining and quantifying the amount of fibrotic tissue in preclinical mouse models and will be presented by Olivia Uitto, Ph.D.

Conference organizers are working together to create a comprehensive program which integrates developments in imaging technologies and molecular imaging agents with applications for drug development, basic science investigations, and clinical translation. Industry exhibits will include the latest advances in pre-clinical and clinical imaging applications to create a “one-stop” molecular imaging educational technology showcase. The WMIC will bring together technically distinct and separate research communities that have a shared vision in the molecular imaging sciences. More than 2,000 participants from across the globe are expected to attend.

### **About Numira Biosciences**

Numira is a rapidly growing provider of specialty contract research services to the pharmaceutical and medical device industries. Through the combination of several novel technologies and capabilities, we provide clients with an unmatched array of pre-clinical services for their research programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and other areas of disease and/or therapy. Moreover, we are a recognized leader in high-resolution, quantitative imaging for drug and device development. Numira, a privately-held company, is venture-backed by vSpring Capital, the Tech Coast Angels, and Crocker Ventures. For more information on Numira, please visit [www.numirabio.com](http://www.numirabio.com).

### **Contact Info:**

Mary Mathis  
Senior Director, Marketing & Communications  
Numira Biosciences Inc.  
Tel: (801) 320-0682 Ext 325  
[mmathis@numirabio.com](mailto:mmathis@numirabio.com)

###